Skip to main content

Table 3 Incidence of treatment-emergent adverse events (all causality) in ≥ 1 participants by intensity

From: Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study

 

Total population (N = 196)

 

Total

n (%)

Mild Intensity

n (%)

Moderate Intensity

n (%)

Severe Intensity

n (%)

Nausea

26 (13.3)

17 (8.7)

7 (3.6)

2 (1.0)

Insomnia

9 (4.6)

6 (3.1)

2 (1.0)

1 (0.5)

Abdominal pain, upper

8 (4.1)

4 (2.0)

1 (0.5)

3 (1.5)

Abnormal dreams

7 (3.6)

4 (2.0)

3 (1.5)

0 (0.0)

Dry mouth

4 (2.0)

3 (1.5)

1 (0.5)

0 (0.0)

Constipation

3 (1.5)

0 (0.0)

2 (1.0)

1 (0.5)

Nervousness

2 (1.0)

2 (1.0)

0 (0.0)

0 (0.0)

Migraine

2 (1.0)

1 (0.5)

1 (0.5)

0 (0.0)

Somnolence

2 (1.0)

2 (1.0)

0 (0.0)

0 (0.0)

Gastrointestinal disorder

2 (1.0)

2 (1.0)

0 (0.0)

0 (0.0)

Vomiting

2 (1.0)

2 (1.0)

0 (0.0)

0 (0.0)